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Abstract 
Predicting resistance to third generation cephalosporins in patients with 
Escherichia coli bacteraemia – a retrospective cohort study. 
Annika Holmgren, Degree Project, Programme in Medicine, 2018. 
Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden. 
 
 
Introduction: Some Enterobacteriaceae can produce enzymes (extended spectrum beta-
lactamases or ESBLs) which make them resistant to certain antibiotics. In Sweden, the 
number of ESBL-bacteremia are increasing and Escherichia coli (E. coli) is the dominant 
bacteria. There are difficulties to initially identify which septic patients are to be suspected of 
infection with multi-resistant Enterobacteriaceae, sometimes resulting in delayed effective 
treatment. There are several potential risk factors to consider when assessing whether a septic 
patient might be infected with ESBL-producing bacteria. Therefore, it would be valuable to 
have indicating factors to facilitate the identification of patients at risk in order to choose 
effective empiric treatment. 
 
Methods: The patients were selected based on the occurrence of E. coli-positive blood 
cultures between 1 Jan - 31 Dec 2016. Analyzed factors were age, sex, previous 
hospitalization, recent surgery, use of urinary catheter, living in nursing home, previous 
antibiotic treatment, immunosuppression, hospital care abroad, hospital vs. community 
acquired infection, previous faeces culture with ESBL-E. coli and previous urine and/or blood 
culture with ESBL-E. coli. A multivariate analysis was performed for variables with a uni-
variate p-value <0.2 and statistical significance was established at £0.05. 
 
Results: A total of 470 patients were evaluated, with 485 cases of bacteremia. Three 
parameters gained statistical significance: hospital care abroad (OR=3.4, 95%CI=1.1-10.4, 
p=0.037), previously ESBL-positive in faeces (OR=8.1, 95%CI=1.0-65.4, p=0.050) and 
previously ESBL-positive in blood and/or urine (OR=54.5, 95%CI=11.2-256.5, p<0.001). 
 
Conclusion: In this retrospectively conducted survey of patients with E. coli bacteremia, we 
found that previously detected ESBL-E. coli in blood, urine or faeces and previous hospital 
care abroad were predicting factor for bacteremia with ESBL-producing E. coli. 
 
KEY WORDS: ESBL; E. coli; bacteremia; risk factors 
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Introduction 
 
The development of antibiotics as a treatment of bacterial infections is to be regarded as one 
of the greatest successes in modern medicine (1). Thanks to antibiotics several simple as well 
as more difficult infections can be treated and thereby many patients can be cured. However, 
there is a growing threat to this way of treatment in terms of multi-resistant bacteria. 
Enterobacteriaceae producing enzymes, which make them resistant to third generation 
cephalosporins, also known as extended spectrum beta-lactamases (ESBLs), are a big problem 
worldwide. (2). In 1983 the first rapport regarding plasmid encoded β-lactamases with 
extended spectrum was published and since then several additional enzymes within this group 
have been identified (3). This is a growing issue in the treatment of bacterial infections also in 
the Swedish healthcare system. In 2014, 8 902 new cases of ESBL-producing bacteria were 
identified among Swedish patients of which Escherichia coli (E. coli) represented 89% (4). In 
2016 respectively, 10 659 cases were identified, which shows of a significant increase in 
number of cases per year (5). 
 
In Sweden, 609 cases of ESBL-bacteremia were reported in 2016 and E. coli is the dominant 
ESBL-producer (6). Other bacteria have also been identified with ESBL-producing abilities 
such as Klebsiella pneumoniae, Salmonella, Pseudomonas, Proteus and Enterobacter but in 
Sweden these are less common than E. coli. The second largest group after E. coli is K. 
pneumoniae which represented 7% of the ESBL-cases in Sweden 2014 (7). 
 
Bacteria with the ability to produce ESBLs have found an effective way to evade several 
types of antibiotics. In many cases this leads to a delayed effective treatment which can result 
in severe consequences for the patient since the time from infection to correct treatment is of 
essence for these kind of systemic infections (8). ESBL-producers are in most cases 
susceptible to piperacillin/tazobactam and carbapenems which are subgroups of beta-lactams, 
but they are almost always resistant to cephalosporins (9). It is also common to see co-
resistance to fluoroquinolones, aminoglycosides and trimethoprim-sulfamethoxazole which 
limits the choice of effective treatment even further.  
 
Beta-lactams are considered to be the treatment of choice for several different types of 
infections such as urinary tract infections and septicemia. Patients arriving at the emergency 
department and who suffers from a systemic infection are often treated empirically while 
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awaiting analysis of the drug resistance pattern from the blood cultures. In majority of the 
cases the chosen antibiotic will not have any effect against ESBL-producing bacteria (10). 
The condition of a patient with a systemic infection with ESBL-producing bacteria can 
drastically deteriorate, and the risk of mortality increases, if effective treatment is not 
provided at an early stage (11). 
 
Beta-lactams contain a structure called beta-lactam ring. This structure binds to penicillin-
binding proteins (PBPs) in the bacterial cell wall by imitating its building blocks (12). The 
cell wall consists of alternating N-acetylmuramic acid (NAM) and N-acetylglucosamine 
(NAG) which creates a stable outer wall towards the surrounding environment. Every NAM-
unit has an associated pentapeptide and the linkage between two NAM-pentapeptides is 
catalyzed by PBPs (13,14). When the beta-lactam ring binds to the PBPs the crosslinking 
between peptidoglycans is interrupted and the cell wall synthesis is thereby blocked resulting 
in lysis of the bacteria (15). Beta-lactamases work through hydrolyzing the beta-lactam ring 
of the antibiotic which make many penicillins and cephalosporins ineffective (16). Unlike 
regular beta-lactamases, ESBLs can inactivate beta-lactams with extended anti-bacterial 
spectrum such as third generation cephalosporins (17).  
 
There are multiple ways for bacteria to develop resistance to beta-lactams besides producing 
beta-lactamases. One mechanism is the acquirement of changes in the active site of the PBPs, 
lowering the affinity of the beta-lactam ring to the PBPs (18). Another way to avoid the 
antibacterial effect of the beta-lactam is to decrease the number of outer membrane proteins 
(OMPs). The beta-lactam has to either diffuse through the membrane or be transported via 
protein channels in the outer membrane of gram-negative bacteria such as E. coli in order to 
reach the PBPs in the inner plasma membrane. By lowering the expression of OMPs, the 
permeability for beta-lactams is decreased and the antibacterial effect thereby impaired (19). 
The bacteria can also develop a resistance mechanism which consist of pumping the beta-
lactam out of the bacteria via efflux pumps (20). In this way, antibiotics in the periplasm are 
pumped out into the surroundings and the antibiotic effect inside the bacteria is thereby 
absent. Consequently, there are several ways for bacteria to avoid antibiotics, but the 
production of beta-lactamase is the most common and important mechanism among gram-
negative Enterobacteriaceae such as E. coli and thereby the main focus of this project (21). 
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The genes coding for the ESBL enzymes can be transferred to other bacteria through so-called 
plasmids (22). Plasmids are composed of double stranded DNA which can be replicated 
independently of the chromosomal genetic material in the bacteria. During the transmission of 
the ESBL-genes, specific mobile components known as insertion sequence common regions 
(ISCRs) have been identified on the plasmids. The ISCRs enable the transmission of genes to 
other plasmids as well as to chromosomal genome and through this kind of horizontal 
transmission bacteria can share enzymatic abilities among each other (23). Once the genes are 
transmitted, bacterial cloning enables the spreading within a bacterial strain. Bacterial cloning 
means that the same bacteria is multiplied through division and in that way ESBL-genes from 
one bacteria can be incorporated in the genome of an entire bacterial strain (24). 
 
The most dominant ESBL-producers are the Enterobacteriaceae family such as E. coli and K. 
pneumoniae (25) and the bacterial flora inside the gut contains a massive number of bacteria 
and therefor constitutes an optimal environment for transmitting resistance genes. The 
plasmids holding the ESBL-genes can be transmitted between different strains of E. coli but 
also to other bacterial species (26). Besides the ESBLs, the plasmids transferred between the 
bacteria can contain other resistance genes which possibly could explain why 
Enterobacteriaceae often have co-resistance to various antibiotics limiting the methods of 
treatment (27). For several patients with severe infections, co-resistance can be detected 
towards well used treatment options in terms of trimethoprim-sulfamethoxazole, 
aminoglycosides and fluoroquinolones (28). 
 
Furthermore, the ESBLs can be divided into different subgroups. According to the Swedish 
classification made by Giske et al three groups can be identified: ESBLA, ESBLM and 
ESBLCARBA (29). Subgroup ESBLA contains the enzymes CTX-M, SHV and TEM and is 
internationally classified as ESBL. ESBLM refers to the acquirement of plasmid mediated 
AmpC (not chromosomal AmpC) and include enzymes such as AAC and CMY. Finally, 
ESBLCARBA contains enzymes with carbapenemase abilities, for example OXA, MBL and 
KPC (30). The term of ESBLCARBA is a subclassification primarily used in Sweden to describe 
this certain group of enzymes.  
 
Bacteria producing ESBLA are commonly resistant to penicillin, cephalosporins with narrow 
and broad spectrum and the monobactam aztreonam but sensitive to carbapenems, 
cephamycins and ß-lactam/ß-lactamase inhibitor-combinations (31). Bacteria producing 
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ESBLM can inactivate penicillin, combinations of lactamase inhibitors and cephalosporins but 
are often susceptible to aztreonam (32). Due to their carbapenemase activity, bacteria 
producing ESBLCARBA are resistant to carbapenems which usually are the antibiotics of choice 
when treating infections with ESBL-producing bacteria (33). 
 
The AmpC-enzymes of Enterobacteriaceae are commonly encoded in the chromosomal 
bacterial genome and expressed at low levels, usually not generating any beta-lactam 
resistance (34). However, an acquired mutation of the AmpC-promotor can induce 
overexpression of the gene, conferring resistance to extended spectrum cephalosporins (35). 
Besides the overexpression of chromosomal AmpC, the frequency of plasmid encoded AmpC 
is increasing (36). Plasmid-mediated AmpC-enzymes are not as common as the chromosomal 
variant but can confer a broader spectrum of resistance (37). There are also combinations of 
chromosomal and plasmid-encoded AmpC, further increasing the resistance to antibiotics. For 
the scope of this project, AmpC is included in the category of ESBLs due to the growing issue 
of E. coli producing AmpC-enzymes. 
 
There has been much speculation regarding the potential risk factors for becoming colonized 
with ESBL-producing Enterobacteriaceae. One of the potential risk factors is travelling to 
countries with high prevalence of these multi-resistant bacterial strains. Studies made on 
healthy travelers who left stool samples after travelling outside northern Europe showed that 
24% of the participants had become colonized with resistant Enterobacteriaceae (38). Based 
on studies conducted in Sweden, the public health authority estimates the prevalence of 
colonization within the Swedish population to be about 5% (39). Nevertheless, monitoring 
studies shows that 42% of colonized patients were still carriers after one year and 27% were 
again positive after one or more previous negative tests (40). Considering that it is possible to 
at first receive a negative carrier test and then a positive one, it becomes problematic to 
determine when a patient no longer is colonized solely based upon these screening tests. 
 
Among patients colonized with ESBL-producing enterobacteriaceae who avoid developing an 
infection, the carriage will likely remain undetected and these patients will compose a risk of 
transmitting the multi-resistant bacteria to others. It is unfortunately difficult to predict which 
patients are at risk of becoming persistent carriers. For some patients the bacteria disappear 
within a year from infection, but studies show that colonization with ESBL-producing E. coli 
in the gut can lead to a persistent carriage for up to five years (41). The colonization entails an 
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increased risk of severe infection and previous studies have shown prolonged hospitals stays 
and increased mortality amongst patients who suffers from infection with ESBL-producing 
bacteria (42). 
 
The over-prescription of antibiotics is known to be a prominent factor in the emergence of 
multi-resistant strains among bacteria (43). According to WHO 2016, cephalosporins and 
quinolones compose two of the most critically important subclasses of antibiotics in human 
medicine when treating serious bacterial infections (44). Necessary and unnecessary 
prescription of primarily extended spectrum cephalosporins and the uncontrolled use of 
antibiotics abroad promote development of resistance in general and the development of 
multi-resistant Enterobacteriaceae in particular (45). The use of antibiotics to animals 
contributes to the problem because of the evolvement of resistant bacterial strains in this area 
as well. These strains can then be transmitted further to humans through direct contact or 
through the food chain (46).  
 
Hospitalization is another potential risk factor of being colonized and infected with multi-
resistant Enterobacteriaceae (47). Bacteria can circulate due to insufficient hygiene among 
patients or health care professionals, through overcrowded hospital rooms or to inadequately 
disinfected medical instruments. During 2016, a hospital in Stockholm county suffered from 
an outbreak of ESBL-producing Enterobacteriaceae. In total, 55 patients were affected from 
autumn 2015 to June 2016 (48). This resulted in several measurements regarding hygiene 
routines to limit further transmission. Studies have also shown a connection between 
colonization with primarily ESBL-producing E. coli and living in nursing homes (49). 
However, it is difficult to establish the origin of the bacteria since patients living in nursing 
homes often need hospital care and might have brought the bacteria to the hospitals and the 
other way around (50, 51). 
 
Surgical procedures are considered to be another risk factor for colonization and infection 
with resistant bacteria (52). Whether the increased risk of infection after surgical procedures 
is due to prior colonization of the patient, multi-resistant bacteria in the surrounding hospital 
environment or contamination during or after the procedure is difficult to determinate. For 
patients undergoing complicated surgery it is common with urinary catheterization during 
and/or after the procedure. This alone composes a risk of infection with ESBL-producing 
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Enterobacteriaceae (53). Consequently, the risk of infection among patients hospitalized due 
to surgical procedures with remaining catheters is most likely significantly increased. 
 
Our immune system is an important part in the defense against bacteria. Due to this known 
fact it is near at hand to draw the conclusion that different forms of immunosuppression are 
likely to compose another risk for infection with above mentioned bacteria. Studies made 
from a urological section in a Spanish hospital show a connection between 
immunocompromised patients and a higher incidence of ESBL-producing bacteria (54).  
 
In conclusion, there are many potential risk factors to consider when attempting to assess 
whether a patient with bacteremia is infected with ESBL-producing Enterobacteriaceae or not. 
Therefore, it would be of value to have a few indicating factors to facilitate the identification 
of these patients at risk in order to choose adequate treatment. Besides potentially contributing 
to an improved patient health care it would also lower unnecessary prescription of extended 
spectrum antibiotics by further indicating which patients are especially at risk. By 
investigating whether above mentioned risk factors are current in the Gothenburg health care 
system, the hope is to ease the clinical assessment and to further indicate optimal treatment 
for patients with bacteremia. 
 
Aim 
The aim of this study was to find predicting factors to identify patients with ESBL-E. coli 
bacteremia within the Gothenburg health care system in order to provide adequate treatment. 
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Method 
 
Setting and study design 
The study was retrospectively conducted at the Sahlgrenska University Hospital. Sahlgrenska 
University Hospital is a large tertiary hospital at five different locations in Gothenburg and 
Mölndal, with approximately 1 950 hospital beds distributed on 50 departments.  
 
Data collection 
The electronic patient record system Melior was used to examine the medical history of the 
patients. Information on patient laboratory data was obtained from the laboratory data system.  
 
Ethics 
According to current regulation on student degree projects, ethical review board clearance 
was not needed for this project. Patients were not asked for consent to participate in this 
survey. However, to preserve the patients’ integrity the data was unidentified after the data 
collection was completed. 
  
Inclusion and exclusion criteria 
The patients were selected based on the occurrence of a positive blood culture with E. coli. 
The blood samples were collected between 1 January and 31 December 2016. A list with all 
positive blood culture results was obtained from the laboratory. The list was further adjusted 
to solely include one E. coli-sample per patient per month. This limitation was made to 
demarcate the number of bacteremic episodes for each patient. Several positive results within 
one month were therefor considered to be one infection with E. coli.  
 
Variables analyzed  
The factors chosen for analysis were age, sex, hospitalization within a year before admission, 
surgical procedure within a month, urinary catheter within a month, living in a nursing home, 
treatment with fluoroquinolones or cephalosporins within three months, immunsuppression, 
hospital care abroad, if the current bacteremia was hospital or community acquired, positive 
faeces culture with ESBL-producing E. coli within two years and positive urine and/or blood 
culture with ESBL-producing E. coli within two years.  
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The potential risk factors were analyzed based on the occurrence of ESBL-bacteremia or not. 
Among the patients classified as ESBL-positive, both ESBLA and ESBLM were included. 
Consequently, E. coli non-susceptible to one or more 2nd-3rd generation cephalosporins 
and/or with AmpC-acquirement were included. 
 
The definition of hospitalization was set to at least one overnight hospital stay within the last 
year in addition to the episode when the positive culture was obtained. This category only 
comprises hospital care registered in the Sahlgrenska University Hospital electronic patient 
records system. It does not include private hospital care or if a patient received hospital care 
outside Gothenburg, if not specifically stated in the patient medical records. In a handful of 
cases, information concerning previous hospitalization or transfer from another hospital were 
obtainable and these patients were consequently classified with a positive result.  
 
Regarding surgical procedures, the assessment was made based on the performed procedure. 
Surgery involving larger incisions in the skin to remediate underlying structures was 
classified as positive result because of the generally increased risk of infection. According to 
this division, e.g. abdominal and thoracic surgery, orthopedic procedures as well as skin 
transplants were included in the surgical category. Also, other invasive procedures such as 
transuretral resection of the prostate (TURP), transuretral elimination of vesical tumors and 
prostate biopsies were equate with a positive result. Procedures considered less relevant for 
the current question and therefore classified with a negative result, were for instance smaller 
skin excisions, suturing of traumatic wounds, transluminal procedures such as percutaneous 
coronary intervention (PCI) and diagnostically endoscopic examinations e.g. gastroscopy, 
colonoscopy and cystoscopy. The evaluation and classification were made individually for 
each patient because of the great variation of surgical procedures performed. The timeframe 
for the procedures was set to a month preceding the positive E. coli blood culture.  
 
Previous use of urinary catheter was the next factor which was assessed. Patients who had a 
temporary or indwelling urinary catheter within a month until the day before obtaining a 
positive blood culture, were classified with a positive result in this category. Also, patients 
with suprapubic catheters were included. This category contains solely patients who received 
catheters while hospitalized or if information about previous or current catheter use outside 
the hospital was given from the medical records.  
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Furthermore, patients living in a nursing home before the E. coli-bacteremia were noted with 
a positive score. The definition of nursing home in this paper includes all varieties of 
residency except the patient’s own home, for example short-term accommodations, elderly 
care facilities or variations of temporary group residences. Patients who received health care 
through advanced hospital care at home were categorized with a negative result considering 
that the treatment was performed in the patient’s own habitation.  
 
The use of antibiotics was another risk factor which was evaluated. In this category, treatment 
within the last three months with fluoroquinolones or 2nd-3rd generation cephalosporins were 
examined. This group solely include treatment prescribed and documented during hospital 
care or if information about such treatment in e.g. the primary care was included in the 
medical records.  
 
In question whether a patient was considered to be immunosuppressed or not, an evaluation 
was made individually for each patient. Several varieties of immunsuppression occurred such 
as chemotherapy, combinations of steroid treatments, rheumatic pharmaceuticals etc. 
Concerning chemotherapy, a timeframe was constructed to within the last year. If ongoing 
steroid treatment, doses equal to a daily dosage of 20 mg Prednisolone for at least 30 days 
were classified as positive.  
 
Hospital care abroad is considered another potential risk factor and therefore also examined in 
the medical records. The information was obtained from emergency charts which are filled in 
when the patients arrive to the emergency room. These charts contain information regarding 
previous hospital care abroad within the last year and in some cases even further back in time. 
However, the information given on the emergency charts does not generally include in which 
country the patient received hospital care or the acquired therapy. Consequently, all patients 
who received hospital care abroad, regardless of the country or treatment, were categorized 
with a positive score. In several cases the information in question were absent, and those 
patients were classified with an unknown/negative result in this category. 
 
To determine whether the infection was to be considered hospital or community acquired, a 
timeframe was set. Patients with onset of symptoms of infection within 2 days from arriving 
to hospital were classified as community acquired and attained a negative result in this group. 
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Consequently, patients who obtained symptoms more than 2 days after admission to hospital 
were classified as hospital acquired and received a positive result. 
 
Finally, every positive culture consisting of ESBL-producing E. coli in the last two years from 
the current septic episode were noted. Patients with one or more positive ESBL-culture within 
the last two years, were classified as positive. The assessed material was separated into two 
groups, previous ESBL-producing E. coli in blood and/or urine, and previous ESBL-
producing E. coli in faeces. 
 
When all the data was collected from the medical records, remaining variables such as age at 
the time for the blood samples and gender were compiled.   
 
Statistical analyses  
Statistical analysis was performed using the statistical software package SPSS version 25.0.  
 
The categorical variables were studied separately to observe frequency and distribution within 
each parameter. Proportions were compared using univariate Pearson’s Chi-square test to 
determine significant factors influencing the acquisition of ESBL/AmpC-positive strains. 
Continuous variables were compared by Mann–Whitney U-test.  
 
After the univariate analysis, a multivariate analysis was performed using a backward logistic 
regression model for all variables with a calculated p-value <0.2 in the Chi-square analysis. 
Odds ratios (OR) and 95% confidence interval (CI) were calculated to evaluate the strength of 
any association that emerged and statistical significance was established at £0.05.  
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Results 
 
A total of 470 patients were evaluated in this study, with 485 cases of bacteremia caused by E. 
coli. There were 218 male patients with a total of 228 blood cultures and 252 female patients 
with a total of 257 blood cultures. The median age in the ESBL-positive group was 72 years 
and 74 years in the ESBL-negative group. Strains without production of ESBLs, were located 
in 438 blood cultures (90.3%) while ESBL-producing isolates were identified in 47 blood 
cultures (9.7%).  
 
Among the patients included in this study, a total of 12 patients were classified with more 
than one septic episode. Nine of these patients experienced two separate infectious episodes 
and three patients had three separate infectious episodes. 
 
A Chi-Square test with a cut-off p value of <0.2 was performed (Table 1), which resulted in 
the following factors for further statistical examination: sex (p = 0.015), treatment with 
fluoroquinolones or 2nd-3rd generation cephalosporins within the last three months (p = 
0.095), hospital care abroad (p = 0.006), ESBL-positive in faeces within the last two years (p 
= 0.001) and ESBL-positive in blood and/or urine within the last two years (p < 0.001). These 
factors were further evaluated in a multivariate backward logistic regression model to confirm 
any potential significant value. The residual parameters, described below, were not associated 
with significant outcomes and consequently not further investigated.  
 
Results from the univariate analysis 
Previous hospital admission within the preceding year was not associated with ESBL-
bacteremia (p = 0.378). In total, 236 cases had no previous hospital admission (216 ESBL-
negative blood cultures and 20 ESBL-positive blood cultures) and 249 patients had spent at 
least one night in hospital during the last year (222 ESBL-negative blood cultures and 27 
ESBL-positive blood cultures).  
 
Surgical procedure within one month preceding the blood culture did not result in a 
significantly increased risk for bacteremia with ESBL-E. coli (p = 0.927). In 421 cases, no 
history of recent surgery was discovered (380 ESBL-negative and 41 ESBL-positive blood 
cultures). The number of cases with a positive result in this category was 64 (58 ESBL-
negative blood cultures and six ESBL-positive blood cultures). 
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The analysis did not demonstrate any increased risk for patients living in nursing homes (p = 
0.590). In total, there were 410 cases where the patients were living in their own homes (369 
ESBL-negative blood cultures and 41 ESBL-positive blood cultures) and 75 cases where the 
patients lived in some sort of nursing home (69 ESBL-negative blood cultures and six ESBL-
positive blood cultures). 
 
Concerning the use of urinary catheter within a month preceding the positive blood culture, no 
elevated risk of infection was detected (p = 0.246). Among these cases, 401 patients had no 
record of using urinary catheter within the last month (365 ESBL-negative blood cultures and 
36 ESBL-positive blood cultures) in contrast to 84 patients who previously had received a 
urinary catheter (73 ESBL-negative blood cultures and 11 ESBL-positive blood cultures).  
 
Furthermore, no association was found between immunosuppression and ESBL-bacteremia (p 
= 0.918). Overall, 405 cases concerned patients without immunomodulating treatment (366 
ESBL-negative blood cultures and 39 ESBL-positive blood cultures) and 80 cultures were 
connected to immunodepressed patients (72 ESBL-negative blood cultures and eight ESBL-
positive blood cultures). 
 
Whether the infection was acquired at hospital or in the community did not significantly 
affect the occurrence of ESBL-bacteremia (p = 0.815). In total, there were 407 community 
acquired infections (367 ESBL-negative blood cultures and 40 ESBL-positive blood cultures) 
and 78 cases were classified as hospital acquired (71 ESBL-negative blood cultures and seven 
ESBL-positive blood cultures). 
 
Age was analyzed with the Mann-Whitney U-test and not proven to be a significant factor 
concerning the risk of developing an ESBL-E. coli bacteremia (p = 0.595). Within this 
category, the mean age in the ESBL-negative group was 69 years and the median 74 years. 
Similarly, in the ESBL-positive group the mean age was 68 years and the median 72 years. 
When separated according to gender, in the entire cohort, the mean age for men was 71 years 
and 67 years for women respectively.  
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Results from the logistic regression model 
Treatment with fluoroquinolones or 2nd-3rd generation cephalosporins within the preceding 
three months did not result in a statistically increased risk to acquire a systemic infection with 
ESBL-E. coli (p = 0.461). In total, 420 cases had no history of treatment with the above-
mentioned antibiotics within this period of time (383 ESBL-negative blood cultures and 37 
ESBL-positive blood cultures) and 65 cases had received such treatment (55 ESBL-positive 
blood cultures and ten ESBL-negative blood cultures).  
 
Concerning sex, there was a trend towards a lower risk for women in terms of ESBL-
bacteremia. However, significant results were not obtained in this category in the multivariate 
analysis (p=0.093). In total, 228 blood cultures from male patients were obtained (198 ESBL-
negative blood cultures and 30 ESBL-positive blood cultures) and 257 blood cultures from 
women (240 ESBL-negative blood cultures and 17 ESBL-positive blood cultures).  
 
Hospital care abroad was significantly associated with ESBL-bacteremia (p = 0.037). In 462 
cases, no history of hospital care abroad was discovered (421 ESBL-negative blood cultures 
and 41 ESBL-positive blood cultures) in contrast to 23 patients who previously received 
health care internationally (17 ESBL-negative blood cultures and six ESBL-positive blood 
cultures).  
 
A statistical association was found with previously detected rectal colonization with ESBL-E. 
coli within two years preceding the current blood culture (p=0.050). Within this group, 479 
cases had no history of previously known rectal colonization (436 ESBL-negative blood 
cultures and 43 ESBL-positive blood cultures) in contrast to six cases which were associated 
with a former positive faeces test (two ESBL-negative blood cultures and four ESBL-positive 
blood cultures).   
 
A previously positive ESBL-culture from blood and/or urine within the last two years was 
significantly associated with ESBL-bacteremia (p < 0.001). In total, 472 cases had no 
previous record of ESBL-E. coli in blood and/or urine (436 ESBL-negative blood cultures and 
36 ESBL-positive blood cultures), while 13 cases had a positive preceding ESBL-culture (two 
ESBL-negative and 11 ESBL-positive blood cultures). 
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In summary, three parameters gained statistical significance in the multivariate logistic 
regression analysis: hospital care abroad, previously positive ESBL-cultures from faeces 
within the last two years and previously positive ESBL-cultures from blood and/or urine 
within the last two years (Table 2, Figure 1). Hospital care abroad, as a single predictive 
clinical risk factor, had a sensitivity of 12.8% and a specificity of 96.1%. PPV was calculated 
to 26.0% and NPV to 91.1%. Previously positive ESBL-cultures from faeces gained a 
sensitivity of 8.5% and a specificity of 99.5%. The PPV was calculated to 66.7% and NPV 
91.0%. Previously positive ESBL-cultures from blood and/or urine received a sensitivity of 
23.4% and a specificity of 99.5% when analyzed as an indicator. The PPV for this factor was 
84.6% and NPV 92.4%.  
 
To further assess the results, we created a model to perceive the occurrence of a positive result 
in either one of the parameters which had gained a p-value < 0.05, e.g. hospital care abroad 
and previously positive ESBL-cultures from blood and/or urine. Accordingly, the sensitivity 
was calculated to 34.0% and the specificity to 95.7%. This generated a PPV-value of 45.7% 
and an NPV-value of 93.1%. 
 
TABLE 1. Univariate analysis with Chi-Square and Mann-Whitney U-test to evaluate risk factors indicating bacteremia with ESBL-
producing E. coli.  
 Parameter p value ESBL+ ESBL-   
Age, median  0.595 72 74  
Sex   0.015 
 Men   30 198   
 Women   17 240   
Hospitalizationa  0.378 27 222 
Surgeryb  0.927 6 58 
Nursing homec  0.590 6 69 
Prev. catheter used  0.246 11 73 
Prev. antibiotic treatmente 0.095 10 55 
Immunosuppressions 0.918 8 72 
Health care abroad  0.006 6 17 
Hospital acquired infectionf 0.815 7 71 
Prev. ESBL-positive in 0.001 4 2 
faecesg 
Prev. ESBL-positive in <0.001 11 2 
blood and/or urineh 
 
The quantities given for ESBL+ and ESBL- represent the number of blood cultures and consequently not the number of patients. The 
quantities given for age represent median age. 
ESBL = Extended spectrum beta-lactamase  
E. coli = Escherichia coli 
a Spent at least one night at hospital within the last year in addition to the episode when the E. coli-positive blood culture was obtained. 
b Surgery within the last month preceding the E. coli-positive blood culture. 
c Catheter use within one month preceding the E. coli-positive blood culture. 
d All varieties of residency except the patient’s own home. 
e Treatment with fluoroquinolones or 2nd-3rd generation cephalosporins within the last three months preceding the E. coli-positive blood 
culture. 
f Patients who obtained symptoms of infection more than two days after admission to hospital. 
g Previously ESBL-positive in faeces within the last two years preceding the E. coli-positive blood culture. 
h Previously ESBL-positive in blood and/or urine within the last two years preceding the E. coli-positive blood culture. 
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TABLE 2. Multivariate logistic regression analysis of risk factors for ESBL-producing E. coli isolation. 
 
 Parameter OR 95% CI  p value 
Hospital care abroad 3.4 (1.1-10.4)  0.037 
Prev. ESBL-positive in  8.1 (1.0-65.4)  0.050 
faecesa 
 
Prev. ESBL-positive in blood  54.5 (11.2-265.5)  <0.001 
and/or urineb 
 
ESBL = Extended spectrum beta-lactamase  
E. coli = Escherichia coli 
 
 
a Previously ESBL-positive in faeces within the last two years preceding the E. coli-positive blood culture. 
b Previously ESBL-positive in blood and/or urine within the last two years preceding the E. coli-positive blood culture. 
 
 
 
 
 
 
 
The quantities given for ESBL+ and ESBL- represent the number of blood cultures and consequently not the number of patients.  
ESBL = Extended spectrum beta-lactamase  
E. coli = Escherichia coli 
 
 
a Previously ESBL-positive in faeces within the last two years preceding the E. coli-positive blood culture. 
b Previously ESBL-positive in blood and/or urine within the last two years preceding the E. coli-positive blood culture. 
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FIGURE 1. Diagram displaying the quantities within each parameter with significant results in the 
multivariate logistic regression analysis. The logistic regression analysis evaluate risk factors indicating 
bacteremia with ESBL-producing E. coli 
ESBL + ESBL -
Hospital care abroad Prev. ESBL-positive in faecesa Prev. ESBL-positive 
in blood and/or urineb
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Discussion 
 
In this retrospectively conducted survey of patients with E. coli bacteremia, we found that 
previously detected ESBL-producing bacteria in blood, urine or faeces and previous hospital 
care abroad were predicting factors for bacteremia with ESBL-producing E. coli.  
 
Infections with ESBL-producing Enterobacteriaceae have evolved greatly within the last few 
years (55). The treatment of severe infections caused by these bacteria, such as septicemia 
with ESBL-producing E. coli, becomes problematic due to the risk of an inefficient empirical 
treatment (56). Previous studies have revealed that infections with multi-resistant 
Enterobacteriaceae have a great impact on the clinical outcome (57, 58). Furthermore, studies 
show that early administration of effective antimicrobial treatment is the most important 
parameter regarding survival from septicemia and the mortality increases every hour of 
delayed treatment (59, 60). In the light of this knowledge, multiple studies worldwide have 
been published that have aimed at finding parameters predicting which patients are at risk of 
having bacteremia with ESBL-producing Enterobacteriaceae (61, 62, 63). Different factors 
have been found significant depending on the geographic area and the study population where 
the material is collected, and it is therefore problematic to identify generalizable factors. 
 
The available material regarding such indicative factors for patients in Sweden is limited. The 
results available from international studies are difficult to generalize to patients in Sweden 
due to epidemiological differences and because of differences in health care systems and 
antibiotic prescription tradition. The prevalence of multi-resistant bacteria in Sweden is 
relatively low and it is therefore problematic to generalize results obtained in countries with a 
higher prevalence (64). Risk factors which have been found significant in international studies 
should therefore also be evaluated in this population and hopefully later on be implemented in 
the clinical assessment of these patients.  
 
Our study found three significant parameters indicative for when patients are to be suspected 
to have bacteremia caused by ESBL-producing E. coli. The first factor was previous hospital 
care abroad, without consideration to country or treatment (OR 3.4, 95% CI 1.1-10.4, p value 
= 0.037). This parameter resulted in a positive statistical association and can consequently be 
regarded as a stated risk factor. When analyzed as a predictive parameter, the calculated 
sensitivity was 12.8% and specificity was 96.1% with a PPV and NPV of 26.0% and 91.1% 
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respectively. Consequently, the analysis resulted in a relatively high PPV why it may have 
some value to consider this component in the clinical assessment. A previous Swedish study 
showed an association between the carriage of ESBL-producing E. coli and traveling abroad 
to primarily Asia and Africa where the prevalence of multi-resistant bacteria is high (65). 
Consequently, the risk of colonization and infection with multi-resistant Enterobacteriaceae 
seems to be increased when receiving hospital care abroad or when travelling to areas with a 
high prevalence. The information we received from the emergency charts did not specify the 
country where the hospital care was given. However, one might speculate that receiving 
hospital care in countries with high prevalence of multi-resistant bacteria would compose an 
even higher risk. 
 
The second indicative parameter was previously documented ESBL-producing E. coli in 
faeces (OR 8.1, CI 1.0-65.4, p value = 0.050). When viewed as a single predictor, sensitivity 
was 8.5% and specificity 99.5%. PPV and NPV were 66.7% and 91.0% respectively. Since 
statistical significance was established at £0.05, this factor barely reached significance. 
Consequently, the importance of previous rectal colonization in this population can be 
regarded as a bit uncertain. However, a previous study from the Netherlands indicate that 
isolation of multi-resistant Enterobacteriaceae from any site ought to be regarded as a risk 
factor for ESBL-bacteremia (66). The results from our survey could be explained by the 
limited number of cases. If the same analysis would be made on a larger population, the 
results might be more definite.  
The third parameter that significantly predicted ESBL-bacteremia, was previously 
documented blood and/or urine cultures with ESBL-producing E. coli (OR 54.5, 95% CI 11.2-
265.5, p value < 0.001). When analyzing this as an individual risk factor, sensitivity and 
specificity were 23.4% and 99.5% respectively. PPV and NPV were calculated to 84.6% and 
92.4% respectively. The results indicate that this variable ought to be regarded as an 
important predictor in septic patients. A study performed in Baltimore, USA, display a similar 
association (67). The results from that study revealed that previous colonization or infection 
with ESBL-producing Enterobacteriaceae within the last 6 months was one of the strongest 
associated variables regarding the risk of acquiring ESBL-bacteremia.  
 
To further assess the results, we created a model to analyze the occurrence of a positive 
outcome in either one of the two parameters which had gained a p-value <0.05, e.g. hospital 
care abroad and previously positive ESBL-cultures from blood and/or urine. Accordingly, the 
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sensitivity was calculated to 34.0% and specificity 95.7%. The PPV and NPV were 45.7% 
and 93.1% respectively. According to our constructed model, the sensitivity score did not 
demonstrate a notably high value. Approximately 34% of patients with ESBL-bacteremia will 
be identified based on the occurrence of the analyzed factors. However, the high PPV 
illustrates that these parameters still might have a high indicative value. If E. coli is suspected 
to be the causal agent and the patient have a positive score in either one of these two 
variables, approximately 46% will be infected with an ESBL-producing E. coli-strain and 
antibiotics effective against ESBL-producing bacteria should be administrated.  
 
If either of the variables are negative on the other hand, the probability of bacteremia caused 
by ESBL-producing E. coli is lower and empiric antibiotic coverage for ESBL-producing 
bacteria is not necessary unless the patient is severely ill. Nonetheless, approximately 7% of 
these patients will have an ESBL-bacteremia despite negative scoring on either of these 
parameters and might consequently not respond to treatment with third generation 
cephalosporins.  
 
All of these parameters, are easily accessible in the acute assessment of a patient with 
suspected sepsis. Information whether a patient has received hospital care abroad is 
documented on the emergency chart, filled in when the patient arrives to the emergency room. 
These charts are commonly close at hand in the emergency rooms and the physician in charge 
can easily survey the current category on the chart and be further directed in etiology and 
treatment. Likewise, information regarding previously obtained blood, urine or faeces cultures 
is also easily accessible. All analyzed cultures are registered in the laboratory data system in a 
relatively approachable way and therefore also a parameter which is clinically valuable. To 
obtain information concerning these parameters do not require significant loss of critical time. 
Instead, the acquired information can possibly result in important evidences to determine the 
origin. 
 
The remaining factors analyzed in this survey did not result in significant values. However, 
several of these parameters have attained significant results in studies performed in other 
countries. For example, we did not find a connection between previous treatment with 
fluoroquinolones or 2nd-3rd generation cephalosporins within the last three months, and an 
increased risk of infection with ESBL-E. coli. Although, this association was found in a study 
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performed in Italy (68). The same study also revealed previous hospitalization and urine 
catheterization to be significant risk factors in the examined population.  
 
Another study, performed in Taiwan, identified a connection between patients living in 
nursing homes and an increased risk of bacteremia with Enterobacteriaceae (69). We did not 
find such association in our survey, possibly due to good hygiene routines in many Swedish 
nursing homes. The Taiwanese study also showed recent invasive procedures to be a risk 
factor for bacteremia with above mentioned bacteria, a parameter which was not found 
statistically significant in our population. Accordingly, the results vary depending on 
localization and study population. If this is due to epidemiological differences or as a result of 
differences in health care systems etc., is difficult to determine.  
 
Sex was a parameter which displayed a trend towards a significant value but did not attain a 
significant result in the multivariate analysis. One can speculate that male patients might have 
a higher prevalence of urinary tract pathology due to conditions such as benign prostate 
hyperplasia, prostate cancer etc. These conditions are often treated surgically and are also 
associated with a high prevalence of recurrent infections in need of antibiotic treatment. It is 
known from previous studies that frequent antibiotic treatment benefits the selection of multi-
resistant bacteria such as ESBL-producing E. coli (70, 71). Because of this, speculations can 
be made that male patients might have an increased risk of ESBL-bacteremia. However, such 
speculations were not validated in our study. 
 
Limitations to this study should be noted. There are a few potential sources of error which 
should be taken into consideration. The study material is collected from patient medical 
records and is dependable upon the factual documentation of the requested parameters in the 
medical history. If the parameters were not documented in the records, the collected data will 
be misleading. Also, the accuracy of the collected data is dependent upon whether the 
documentation was made consistently in all records. For example, information regarding the 
use of urinary catheter was discovered to be documented within various posts in the medical 
records. The number of positive outcome in this category might therefore be underestimated 
due to difficulties to thoroughly find the correct information. Consequently, the use of urinary 
catheter might have a larger impact as a risk factor than revealed in this survey. Likewise, the 
collected information regarding previously received medical treatment outside the 
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geographical area comprehended in this study, or the prescription of antibiotics from the 
primary care, might also be underestimated due to the absence of documentation.  
 
One should also mention that the number of cases included in this survey is limited and a 
larger study population would have been desirable to further statistically confirm the results. 
Moreover, one can discuss the individual evaluations made regarding both surgical 
procedures as well as the assessment of what should be considered as immunocompromising. 
These divisions were made primarily based on acquired results from international studies, but 
also on clinical experience attained from medical physicians.  
 
Finally, this survey was performed on patients treated at the Sahlgrenska University Hospital 
and the results can therefore be problematic to generalize to areas with other epidemiological 
conditions. Similar national studies are needed to further confirm these results. The outcome 
should also preferably be evaluated in additional scoring models. 
 
In summary, three specific factors were found associated with increased risk of bacteremia 
with ESBL-producing E. coli. These parameters are easily obtainable without significant loss 
of time in the acute assessment of septic patients. By taking these predicting factors into 
account, we hope to have contributed with an easy to use tool in the evaluation of whether 
antibiotics effective against ESBL-producing bacteria should be administrated to patients with 
suspected gram-negative sepsis.  
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Populärvetenskaplig sammanfattning 
Förutsägande faktorer för att insjukna i blodförgiftning med 
multiresistenta tarmbakterier 
 
Under 2016 drabbades drygt 600 patienter i Sverige av blodförgiftning till följd av 
multiresistenta tarmbakterier. Karaktäristiskt för dessa bakterier är att de producerar ett 
protein som gör dem motståndskraftiga mot vanligt förekommande antibiotika som ofta 
används vid akut behandling av patienter med blodförgiftning. I de flesta fall kan dock dessa 
bakterier behandlas med en annan antibiotikatyp som därmed bör ges när det finns misstanke 
om att en patient kan vara infekterad med multiresistenta tarmbakterier.  
 
I dagsläget är det svårt att identifiera vilka patienter som bör misstänkas vara infekterade med 
multiresistenta tarmbakterier och i många fall leder detta till att den botande behandlingen blir 
fördröjd, något som kan innebära svåra konsekvenser för patienten. Det vore därför värdefullt 
om det kunde finnas hjälpmedel att tillgå som underlättar identifieringen av dessa 
riskpatienter så att rätt behandling kan sättas in i ett tidigt skede. 
 
Studien gjordes på patienter som vårdats på Sahlgrenska Universitetssjukhuset under 1 jan-31 
dec 2016 där sjukvården erhållit en positiv bakterieodling avseende den utvalda 
tarmbakterien. Dessa patienters journaler granskades sedan utefter ett flertal förvalda faktorer. 
 
De faktorer där man kunde se en koppling till en ökad risk att drabbas av blodförgiftning med 
multiresistenta tarmbakterier var erhållen sjukhusvård utomlands samt att man tidigare funnit 
multiresistenta tarmbakterier i blod, urin eller avföring. Resultaten visade att för en patient 
som kommer till sjukhus med tecken på blodförgiftning och antingen har vårdats på sjukhus 
utomlands eller har tidigare odlingar med multiresistenta tarmbakterier så är risken ca 46% att 
orsaken till patientens blodförgiftning är multiresistenta tarmbakterier. Om patienten saknar 
dessa faktorer så är risken istället ca 7%. Genom att beakta dessa parametrar beräknas ca 34% 
av de patienter som drabbats av denna variant av blodförgiftning kunna urskiljas. 
 
I vår studie har vi kunnat identifiera tre specifika faktorer för att insjukna i blodförgiftning 
med multiresistenta tarmbakterier för patienter inom Göteborgs sjukhusvård. Information 
kring dessa parametrar kan enkelt fås fram utan att det innebär en allt för stor tidsförlust vid 
den akuta behandlingen av patienterna. Upplysningar avseende sjukhusvård utomlands finns 
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på de akutblad som fylls i då en patient anländer till Akutmottagningen. Information om 
tidigare bakterieodlingar där man funnit multiresistenta tarmbakterier är även den 
lättillgänglig i sjukhusens datorsystem. Genom att beakta dessa parametrarna hoppas vi 
därmed kunna bidra med ett enkelt hjälpmedel vid bedömningen av vilken typ av behandling 
en patient bör få om det föreligger misstanke om multiresistenta tarmbakterier som orsak till 
blodförgiftningen. 
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